Gamma tocopherol upregulates the expression of 15-S-HETE and induces growth arrest through a PPAR gamma-dependent mechanism in PC-3 human prostate cancer cells

Nutrition and Cancer

Volumn 61, Issue 5, 2009, Pages 649-662

  Campbell, Sharon E ^a   Musich, Phillip R ^a   Whaley, Sarah G ^a   Stimmel, Julie B ^b   Leesnitzer, Lisa M ^b   Dessus Babus, Sophie ^a   Duffourc, Michelle ^a   Stone, William ^a   Newman, Robert A ^c   Yang, Peiying ^c   Krishnan, Koyamangalath ^a,c  

^a EAST TENNESSEE STATE UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ARACHIDONATE 15 LIPOXYGENASE; CYCLIN D1; CYCLIN D3; FATTY ACID; GAMMA TOCOPHEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BCL 2;

ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; FATTY ACID METABOLISM; HUMAN; HUMAN CELL; MALE; METABOLIC REGULATION; PROSTATE CANCER; PROTEIN EXPRESSION; UPREGULATION;

ADENOCARCINOMA; ARACHIDONATE 15-LIPOXYGENASE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; EPITHELIAL CELLS; GAMMA-TOCOPHEROL; GENE EXPRESSION; GENE KNOCKOUT TECHNIQUES; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; LIGANDS; MALE; PPAR GAMMA; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN BINDING; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 70449647028     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580902825654     Document Type: Article

References (60)

1. Fair WR, Fleshner NE, and Heston W: Cancer of the prostate: a nutritional disease? Urology 50, 840-848, 1997.
2. Deneo-Pellegrini H, De Stefani E, Ronco A, and Mendilaharsu M: Foods, nutrients and prostate cancer: a case-control study in Uruguay. Br J Cancer 80, 591-597, 1999. (Pubitemid 29213218)
3. Chavarro JE, Stampfer MJ, Campos H, Kurth T, Willett WC, et al.: A prospective study of trans-fatty acid levels in blood and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 17, 95-101, 2008.
4. Fleshner NE, Bagnell P, Klotz L, and Venkateswaran V: Dietary fat and prostate cancer. J Urol 171, S19-S24, 2004.
5. KolonelLN, NomuraAMY, andCooneyRV: Dietary fat and prostate cancer: current status. J Natl Cancer Inst 91, 414-428, 1999.
6. De Marzo AM, Marchi VL, Epstein JI, and Nelson WG: Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Path 155, 1985-1992, 1999.
7. De MarzoAM, Platz EA, Sutcliffe S, Xu J, Gronberg H, et al.: Inflammation in prostate carcinogenesis. Nat Rev Cancer 7, 256-269, 2007.
8. Nelson WG, De Marzo AM, DeWeese TL, and Isaacs WB: The role of inflammation in the pathogenesis of prostate cancer. J Urol 172, S6-S12, 2004.
9. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, et al.: The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 54, 1379-1384, 2008.
10. Stone WL and Papas AM: Tocopherols and the etiology of colon cancer. J Natl Cancer Inst 89, 1006-1014, 1997.
11. Barrie MM: Vitamin E deficiency in the rat: fertility in the female. Biochem J 32, 2134-2137, 1938.
12. Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo JE, et al.: Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 62, 1427S-1430S, 1995.
13. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM, et al.: Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 97, 94-102, 2005.
14. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, et al.: Effect of selenium and vitamin e on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301, 39-51, 2009.
15. Nomura AM, Ziegler RG, Stemmermann GN, Chyou PH, and Craft NE: Serum micronutrients and upper aerodigestive tract cancer. Cancer Epidemiol Biomarkers Prev 6, 407-412, 1997.
16. Bostick RM, Potter JD,McKenzie DR, Sellers TA,Kushi LH, et al. Reduced risk of colon cancer with high intake of vitamin E: the IowaWomen's Health Study. Cancer Res 53, 4230-4237, 1993.
17. Helzlsouer KJ, Huang HY, Alberg AJ, Hoffman S, Burke A, et al.: Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 92, 2018-2022, 2000.
18. Stone WL, Papas AM, LeClair IO, Qui M, and Ponder T: The influence of dietary iron and tocopherols on oxidative stress and ras-p21 levels in the colon. Cancer Detect Prev 26, 78-84, 2002.
19. Cooney RV, Franke AA, Harwood PJ, Hatch-Pigott V, Custer LJ, et al.: Gamma-tocopherol detoxification of nitrogen dioxide: superiority to alphatocopherol. Proc Natl Acad Sci USA 90, 1771-1775, 1993.
20. Jiang Q, Elson-Schwab I, Courtemanche C, and Ames BN: Gammatocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci USA 97, 11494-11499, 2000.
21. Gysin R, Azzi A, and Visarius T: Gamma-tocopherol inhibits human cancer cell cycle progression and cell proliferation by down-regulation of cyclins. FASEB J 16, 1952-1954, 2002.
22. Jiang Q and Ames BN: Gamma-tocopherol, but not alpha-tocopherol, decreases proinflammatory eicosanoids and inflammation damage in rats. FASEB J 17, 816-822, 2003.
23. Jiang Q, Moreland M, Ames BN, and Yin X: A combination of aspirin and gamma-tocopherol is superior to that of aspirin and alpha-tocopherol in anti-inflammatory action and attenuation of aspirin-induced adverse effects. J Nutr Biochem 2008.
24. Himmelfarb J, Kane J, McMonagle E, Zaltas E, Bobzin S, et al.: Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease. Kidney Int 64, 978-991, 2005.
25. Campbell S, StoneW, Whaley S, and Krishnan K: Development of gammatocopherol as a colorectal cancer chemopreventive agent. Crit Rev Oncol Hematol 47, 249-259, 2003.
26. Campbell SE, Stone WL, Lee S, Whaley S, Yang H, et al.: Comparative effects of RRR-alpha- and RRR-gamma-tocopherol on proliferation and apoptosis in human colon cancer cell lines. BMC Cancer 6, 13, 2006.
27. Campbell SE, Stone WL, Whaley SG, Qui M, and Krishnan K: Gamma tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma expression in SW 480 human colon cancer cell lines. BMC Cancer 3, 2003.
28. Murphy GJ and Holder JC: PPAR gamma agonists: therapeutic role in diabetes, inflammation, and cancer. Trends Pharmacol Sci 21, 469-474, 2000.
29. Gurnell M, Savage DB, Chatterjee VK, and O'Rahilly S: The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab 88, 2412-2421, 2003.
30. Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, et al.:Adominant-negative peroxisome proliferator-activated receptor gamma (PPAR gamma) mutant is a constitutive repressor and inhibits PPAR gamma-mediated adipogenesis. J Biol Chem 275, 5754-5759, 2000.
31. Nichols JS, Parks DJ, Consler TG, and Blanchard SG: Development of a scintillation proximity assay for peroxisome proliferator-activated receptor ligand binding domain. Anal Biochem 257, 112-119, 1998.
32. Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, et al.: Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia 7, 280-293, 2005.
33. Lee CJ, Han JS, Seo CY, Park TH, Kwon HC, et. al.: Pioglitazone, a synthetic ligand for PPARgamma, induces apoptosis in RB-deficient human colorectal cancer cells. Apoptosis 11, 401-411, 2006.
34. Huang JT,Welch JS, Ricote M, BinderCJ,Willson TM, et al.: Interleukin-4- dependent production of PPAR-[gamma] ligands in macrophages by 12/15- lipoxygenase. Nature 400, 378-382, 1999.
35. Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, et al.: S15S-hydroxyeicosatetraenoic acid activates peroxisome proliferatoractivated receptor gamma and inhibits proliferation in pc3 prostate carcinoma cells. Cancer Res 61, 497-503, 2001.
36. Hsi LC, Wilson LC, and Eling TE: Opposing effects of 15-lipoxygenase- 1 and -2 metabolites on mapk signaling in prostate. alteration in peroxisome proliferator-activated receptor gamma.JBiolChem277, 40549, 2002.
37. Chen GG, Lee JF, Wang SH, Chan UP, Ip PC, et al.: Apoptosis induced by activation of peroxisome-proliferator activated receptor-gamma is associated with Bcl-2 and NF-kappaB in human colon cancer. Life Sci 70, 2631-2646, 2002.
38. Li M, Lee TW, Mok TS, Warner TD, Yim AP, et al.: Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. J Cell Biochem 96, 760-774, 2005.
39. Pham H, Banerjee T, Nalbandian GM, and Ziboh VA: Activation of peroxisome proliferator-activated receptor (PPAR)-gamma by 15Shydroxyeicosatrienoic acid parallels growth suppression of androgendependent prostatic adenocarcinoma cells. Cancer Lett 189, 17-25, 2003.
40. Brash AR, Boeglin WE, and Chang MS: Discovery of a second 15Slipoxygenase in humans. Proc Natl Acad Sci USA 94, 6148-6152, 1997.
41. Shappell SB, Boeglin WE, Olson SJ, Kasper S, and Brash AR: 15- lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am J Pathol 155, 235-245, 1999.
42. Tang DG, Bhatia B, Tang S, and Schneider-Broussard R: 15-lipoxygenase 2 (15-LOX2) is a functional tumor suppressor that regulates human prostate epithelial cell differentiation, senescence, and growth (size). Prostaglandins Other Lipid Mediat 82, 135-146, 2007.
43. Tang S, Bhatia B, Maldonado CJ, Yang P, Newman RA, et Al.: Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. J Biol Chem 277, 16189-16201, 2002.
44. Shankaranarayanan P and Nigam S: IL-4 induces apoptosis in A549 lung adenocarcinoma cells: evidence for the pivotal role of 15- hydroxyeicosatetraenoic acid binding to activated peroxisome proliferatoractivated receptor gamma transcription factor. J Immunol 170, 887-894, 2003.
45. Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, et al.: Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I[kappa]B kinase. Nature 403, 103-118, 2000.
46. Wang C, Fu M, D'Amico M, Albanese C, Zhou JN, et al.: Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin d1. Mol Cell Biol 21, 3057-3070, 2001.
47. Chen F,Wang M, O'Connor JP, HeM, Tripathi T, et al.: Phosphorylation of PPARgamma via active ERK1/2 leads to its physical association with p65 and inhibition of NF-kappabeta. J Cell Biochem 90, 732-744, 2003.
48. Kim EK, Kwon KB, Koo BS, Han MJ, Song MY, et al.: Activation of peroxisome proliferator-activated receptor-gamma protects pancreatic betacells from cytokine-induced cytotoxicity via NF kappaB pathway. Int J Biochem Cell Biol 39, 1260-1275, 2007.
49. Legrand AB, Lawson JA, Meyrick BO, Blair IA, and Oates JA: Substitution of 15-hydroxyeicosatetraenoic acid in the phosphoinositide signaling pathway. J Biol Chem 266, 7570-7577, 1991.
50. Wallukat G, Nemecz G, Farkas T, Kuehn H, and Wollenberger A: Modulation of the beta-adrenergic response in cultured rat heart cells: I. betaadrenergic supersensitivity is induced by lactate via a phospholipase A2 and 15-lipoxygenase involving pathway. Mol Cell Biochem 102, 35-47, 1991.
51. Bazan HEP: Cellular and molecular events in corneal wound healing: significance of lipid signalling. Exp Eye Res 80, 453-463, 2005.
52. Nony PA, Kennett SB, Glasgow WC, Olden K, and Roberts JD: 15(S)- lipoxygenase-2 mediates arachidonic acid-stimulated adhesion of human breast carcinoma cells through the activation of TAK1, MKK6, and p38 MAPK. J Biol Chem 280, 31413-31419, 2005.
53. Profita M, Sala A, Riccobono L, Pace E, Paterno A, et al.: 15(S)-HETE modulates LTB4 production and neutrophil chemotaxis in chronic bronchitis. Am J Physiol Cell Physiol 279, C1249-C1258, 2000.
54. Subbarayan V, Krieg P, Hsi LC, Kim J, Yang P, et al.: 15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid througha negative feedback mechanism that involves peroxisome proliferatoractivated receptor gamma. Oncogene 25, 6015-6025, 2006.
55. Spector AA, Gordon JA, and Moore SA: Hydroxyeicosatetraenoic acids (HETEs). Prog Lipid Res 27, 271-323, 1988.
56. Yang X, Downes M, Yu RT, Bookout AL, He W, et al.: Nuclear receptor expression links the circadian clock to metabolism. Cell 126, 801-810, 2006.
57. Canaple L, Rambaud J, Dkhissi-Benyahya O, Rayet B, Tan NS, et al.: Reciprocal regulation of brain and muscle arnt-like protein 1 and peroxisome proliferator-activated receptor alpha defines a novel positive feedback loop in the rodent liver circadian clock. Mol Endocrinol 20, 1715-1727, 2006.
58. Kaeffer B and Pardini L: Clock genes of mammalian cells: practical implications in tissue culture. In Vitro Cell Dev Biol Anim 41, 311-320, 2005.
59. Limor R, Sharon O, Knoll E, Many A, Weisinger G, et al. Lipoxygenasederived metabolites are regulators of peroxisome proliferator-activated receptor gamma-2 expression in human vascular smooth muscle cells. Am J Hypertens 21, 219-223, 2008.
60. Adams M, Reginato MJ, Shao D, Lazar MA, and Chatterjee VK: Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 272, 5128-5132, 1997.